[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377878-105":59,"doc-detail-377878-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumour-cells-in-gastrointestinal-cancers-food-for-thought","Circulating tumour cells in gastrointestinal cancers: food for thought?","","Reviewing circulating tumour cells (CTCs) in gastrointestinal cancers, the text frames metastasis as the key driver of mortality and explains why CTCs in blood signal poor outcomes. It outlines CTC biology, including dissemination and seeding mechanisms, and highlights the limitations created by low cell abundance and restricted biomarkers. It further contrasts antigen-dependent and antigen-independent isolation technologies and notes clinical relevance through FDA-approved platforms, prognostic biomarkers, and ongoing efforts toward targeted antimetastasis strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumour-cells-in-gastrointestinal-cancers-food-for-thought/377878/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumour-cells-in-gastrointestinal-cancers-food-for-thought/377878.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do circulating tumour cells (CTCs) play in gastrointestinal cancer metastasis?","Question",{"text":112,"@type":113},"CTCs support metastasis formation by traveling from the primary GI site to secondary organs. Their presence in patient blood correlates with poor clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is isolating CTCs in gastrointestinal cancers considered difficult?",{"text":117,"@type":113},"CTCs are rare in peripheral blood and there are limited biomarker options for reliable identification. This scarcity makes isolation challenging.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the two main categories of technologies used to isolate CTCs in GI cancers?",{"text":121,"@type":113},"Technologies are grouped into antigen-dependent methods, which rely on tumour-specific markers, and antigen-independent methods, which use distinct biophysical properties of CTCs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},377878,1790313369,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nREVIEW ARTICLE OPEN   \nCellular and Molecular Biology  \nCirculating tumour cells in gastrointestinal cancers: food for thought?  \nSimran Asawa1,2, Manuel Nüesch1,2, Ana Gvozdenovic1 and Nicola Aceto 1 ✉  \n© The Author(s) 2023  \n|  |  |  |\n| --- | --- | --- |\n|  | Gastrointestinal (GI) cancers account for 35% of cancer-related deaths, predominantly due to their ability to spread and generate drug-tolerant metastases. Arising from different locations in the GI system, the majority of metastatic GI malignancies colonise the liver and the lungs. In this context, circulating tumour cells (CTCs) are playing a critical role in the formation of new metastases, and their presence in the blood of patients has been correlated with a poor outcome. In addition to their prognostic utility, prospective targeting of CTCs may represent a novel, yet ambitious strategy in the fight against metastasis. A better understanding of CTC biology, mechanistic underpinnings and weaknesses may facilitate the development of previously underappreciated antimetastasis approaches. Here, along with related clinical studies, we outline a selection of the literature describing biological |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| features of CTCs with an impact on their metastasis forming ability in different GI cancers. |  |  |\n|  | British Journal of Cancer (2023) 128:1981–1990; [https://doi.org/10.1038/s41416-023-02228-8](https://doi.org/10.1038/s41416-023-02228-8) |  |\n|  |  |  |\n\nINTRODUCTION  \nGastrointestinal (GI) cancers are diagnosed in one out of four cancer patients worldwide. They comprise a group of malignant tumours originating from various locations along the GI tract, from the oesophagus to the anus, including supportive glands like liver and pancreas [1] . The most common GI cancers arise in the epithelial tissue of the oesophagus, stomach, pancreas, liver, and colorectum. With 4 .9 million new cases and 3 .9 million deaths in 2020, GI cancers are among the leading cause of cancer-related fatality in both genders [2] .  \nThe majority of GI cancer mortality is associated with metastasis—a complex, multistep process involving systemic spread of tumour cells from the primary site throughout the body, followed by colonisation of secondary organs. The standard of care for GI cancer patients includes approaches such as surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy. However, once the tumour has metastasised to distant organs, with lungs and liver being the most frequent sites, therapeutic options become increasingly narrower [3–6] . Typically, metastatic lesions become clinically visible in GI cancer patients in the years that follow surgical removal of the primary tumour [7–10] . Hence, identifying key drivers of the metastatic process is an essential step to facilitate the development of novel therapeutic strategies that may prevent and/or eradicate metastasis.  \nIn case of most solid tumours, including GI malignancies, growing cancerous lesions may shed cells in the bloodstream which can travel to distant organs and form metastases. These pioneers of the metastatic process are referred to as circulating  \ntumour cells (CTCs) . Though relatively little is known about the mechanisms that influence dissemination and seeding of CTCs, it is well proven that increased numbers of CTCs in blood correlate with poor prognosis in patients [11] . Owing to the rarity of these cells in the peripheral circulation and a limited set of biomarkers for their identification, isolation of CTCs has been notoriously challenging [12] . Several technologies, each with their own set of advantages and disadvantages, are employed for CTC isolation in GI cancers. They can be broadly divided into two categories: antigen-dependent (based on the unique markers expressed by tumour cells but absent in other circulating blood cells) and antigen-independ","cbCaidFOHJWiT51N","https://ap.wps.com/l/cbCaidFOHJWiT51N","pdf",729992,"English","# Introduction\n## Clinical relevance of CTCs in GI cancers\n## CTC isolation technologies (antigen-dependent vs antigen-independent)\n## Prognostic utility and clinical monitoring","[{\"question\":\"What role do circulating tumour cells (CTCs) play in gastrointestinal cancer metastasis?\",\"answer\":\"CTCs support metastasis formation by traveling from the primary GI site to secondary organs. Their presence in patient blood correlates with poor clinical outcomes.\"},{\"question\":\"Why is isolating CTCs in gastrointestinal cancers considered difficult?\",\"answer\":\"CTCs are rare in peripheral blood and there are limited biomarker options for reliable identification. This scarcity makes isolation challenging.\"},{\"question\":\"What are the two main categories of technologies used to isolate CTCs in GI cancers?\",\"answer\":\"Technologies are grouped into antigen-dependent methods, which rely on tumour-specific markers, and antigen-independent methods, which use distinct biophysical properties of CTCs.\"}]","Circulating tumour cells in gastrointestinal cancers: food for thought? | PDF",1790227475,25]